 |
|
LIAI Researchers Discover New Cellular Mechanism That Will Significantly Advance Vaccine Development
June 17, 2008La Jolla Institute for Allergy & Immunology (LIAI) scientists have discovered one for the textbooks. Their finding, reported Friday in the scientific journal Immunity, illuminates a new, previously unknown mechanism in how the body fights a virus. The finding runs counter to traditional scientific understanding of this process and will provide scientists a more effective method for developing vaccines.
"Our research grew from the question, "why do you get good antibody responses to some parts of (virus) pathogens and poor responses to other parts?" said LIAI scientist Shane Crotty, Ph.D., the lead researcher on the paper, "Selective CD4 T cell help for antibody responses to a large viral pathogen: deterministic linkage of specificities." Alessandro Sette, Ph.D., a renowned vaccine expert and director of the LIAI Center for Infectious Disease, also was a key contributor on the study. Dr. Crotty said the team studied the smallpox vaccine, considered the "gold standard" of vaccines, and found some startling answers.
"We expected one thing based on textbook knowledge and that didn't happen at all," he said. It was known previously that getting a good antibody response requires two different cells of the immune system -- B cells and CD4 T cells, both soldiers in the immune system's defensive army. Antibody responses are important because they help the body fight off viruses and they also are key to vaccine development. Surprisingly, however, Dr. Crotty said the researchers found that B cells and CD4 T cells recognize the same piece of the virus.
"Previously, it was thought that the CD4 T cell could react to any part of the virus, but now we realize it must be specific to the same part as the B cell," he explained. "When you have a hundred different parts, this knowledge makes a big difference. It narrows down the search for the right antigens tremendously."
Scientists use knowledge of which antigens (virus pieces) trigger an antibody attack to develop vaccines. Vaccines work by exposing the individual to a milder form of a particular virus, so that the body makes antibodies to fight off the virus. Consequently, if the individual is later exposed to the actual virus, the body already has an army of antibodies built up that can fight off this stronger viral attack before it can overtake the body and cause sickness.
With the knowledge gained from the LIAI study, scientists will now be able to more easily figure out the most important viral pieces to focus on in developing a vaccine. "The fact that it requires two components to fight the (virus) pathogen is important to understand," Dr. Crotty said. "So now when we find out which viral pieces are producing a strong response from the B cells, we can cross check that against the viral pieces eliciting a good response from the CD4 T cells. The point at which these virus pieces cross - in other words where the same piece is eliciting a response from both the B cells and CD4 T cells - then we know we have found our best candidate for creating a vaccine."
About LIAI
Founded in 1988, the La Jolla Institute for Allergy & Immunology is a nonprofit medical research center dedicated to increasing knowledge and improving human health through studies of the immune system. Scientists at the institute carry out research searching for cures for cancer, allergy and asthma, infectious diseases, and autoimmune diseases such as diabetes, inflammatory bowel disease and arthritis. LIAI's research staff includes more than 100 Ph.Ds.
La Jolla Institute for Allergy & Immunology
"Previously, it was thought that the CD4 T cell could react to any part of the virus, but now we realize it must be specific to the same part as the B cell," he explained. "When you have a hundred different parts, this knowledge makes a big difference. It narrows down the search for the right antigens tremendously."
Scientists use knowledge of which antigens (virus pieces) trigger an antibody attack to develop vaccines. Vaccines work by exposing the individual to a milder form of a particular virus, so that the body makes antibodies to fight off the virus. Consequently, if the individual is later exposed to the actual virus, the body already has an army of antibodies built up that can fight off this stronger viral attack before it can overtake the body and cause sickness.
With the knowledge gained from the LIAI study, scientists will now be able to more easily figure out the most important viral pieces to focus on in developing a vaccine. "The fact that it requires two components to fight the (virus) pathogen is important to understand," Dr. Crotty said. "So now when we find out which viral pieces are producing a strong response from the B cells, we can cross check that against the viral pieces eliciting a good response from the CD4 T cells. The point at which these virus pieces cross - in other words where the same piece is eliciting a response from both the B cells and CD4 T cells - then we know we have found our best candidate for creating a vaccine."
About LIAI
Founded in 1988, the La Jolla Institute for Allergy & Immunology is a nonprofit medical research center dedicated to increasing knowledge and improving human health through studies of the immune system. Scientists at the institute carry out research searching for cures for cancer, allergy and asthma, infectious diseases, and autoimmune diseases such as diabetes, inflammatory bowel disease and arthritis. LIAI's research staff includes more than 100 Ph.Ds.
La Jolla Institute for Allergy & Immunology
Vaccine Development Current Events and Vaccine Development News RSSKeeping herpes infection in check: Pitt researchers describe immune system strategies
Herpes simplex virus type I can cause bouts of cold sores, blindness and potentially lethal encephalitis when it reawakens from a quiescent state in the nerve cells it infects.
Purifying parasites with light
Researchers have developed a clever method to purify parasitic organisms from their host cells, which will allow for more detailed proteomic studies and a deeper insight into the biology of organisms that cause millions of cases of disease each year.
Cell removal technique could lead to cheaper drugs
Researchers at the University of Edinburgh have pioneered a simple way to remove dead cells from cell cultures used to make protein-based drugs, which are increasingly prescribed to treat a range of illnesses.
UTMB researchers test new vaccine to fight multiple influenza strains
A universal vaccine effective against several strains of influenza has passed its first phase of testing, according to Dr. Christine Turley of the University of Texas at Galveston.
India continues to progress in AIDS vaccine development efforts
A second Phase I AIDS vaccine clinical trial in India was successfully completed, the Indian Council of Medical Research, the National AIDS Control Organization and the International AIDS Vaccine Initiative announced. The results of the trial of an MVA-based AIDS vaccine candidate (TBC-M4), which was conducted in Chennai, indicated that the vaccine candidate had acceptable levels of safety and was well tolerated.
Towards understanding bluetongue outbreaks
A recent article published in Virology (www.elsevier.com/locate/yviro), reports the identification of a bluetongue virus strain that caused the northern European Bluetongue outbreak in 2006. Comparison of the virus strain with the sequences of other previously isolated strains showed that it originated in sub-Saharan Africa, rather than from vaccine strains or strains circulating in southern Europe.
A protein sequence associated with Huntington's disease may become life-saving vaccine component
On June 10, 2008 the scientific journal "Vaccine" published a paper by the Massachusetts based biotech company Cure Lab, Inc., demonstrating that a protein sequence important in neurodegenerative Huntington's disease can be safely used as a new generation of vaccine adjuvants.
Challenges of HIV-1 subtype diversity
A review article in the New England Journal of Medicine explores the genetic variation of HIV-1 and its implications for preventing and treating the disease. Francine McCutchan, Ph.D., a researcher with the U.S. Military HIV Research Program, co-authored the article, which appeared in the April 10, 2008 edition.
Exhaustion of HIV-specific T cells may be caused by chronic exposure to virus
The "exhaustion" of immune cells that target HIV appears to result from chronic exposure to the virus, specifically exposure to the particular protein segments targeted by the pathogen-killing HIV-specific CD8 T cells.
New technology for boosting vaccine efficiency
One of the most pressing biomedical issues is the development of techniques that increase the efficiency of vaccines. In a paper published on April 24, 2008 in the journal Vaccine, a Massachusetts's biotechnology company, Cure Lab, Inc. has proposed a new technology for anti-viral vaccination.
More Vaccine Development Current Events and Vaccine Development News Articles
 | AIDS Vaccine Development: Challenges and Opportunities |
 | Networks of Innovation: Vaccine Development at Merck, Sharp and Dohme, and Mulford, 1895-1995 by Louis Galambos Networks of Innovation offers a historical perspective on the manner in which private sector organizations have acquired, sustained, and periodically lost the ability to develop, manufacture, and market new serum antitoxins and vaccines. The primary focus is on the H. K. Mulford Company, on Sharp & Dohme, which acquired Mulford in 1929, and on Merck & Co., Inc., which merged with Sharp & Dohme in... |
| New developments with human and veterinary vaccines: 25th OHOLO Biological Conference, Zichron Yaacov, Israel (Progress in clinical and biological research) | |
 | Vaccines: From Concept to Clinic: A Guide to the Development and Clinical Testing of Vaccines for Human Use Designed with academic vaccine researchers in mind, this book presents a road map of how a vaccine develops from an idea in a researcher's imagination, to the lab bench, through preclinical evaluation, and into the clinic for safety and immunogenicity. The result of the editors' own efforts to glean practical information on the steps necessary to manufacture, bottle, and test their vaccines for... |
 | Vaccine Research and Development (Vaccine Research and Developments) by Koff Serving as a complementary series to AIDS Research Reviews - edited by Drs. Wayne C. Koff, Flossie Wong-Staal, and Ronald C. Kennedy (Marcel Dekker, Inc.) - this new series reviews significant advances in immunization research and addresses scientific and public policy challenges for moving candidate vaccines from the laboratory to the population.;Exploring recent progress in immunology, vaccine... |
 | Combination Vaccines: Development, Clinical Research and Approval A diverse team of leading experts comprehensively review the complex biology of a wide variety of vaccine combinations, as well as the technical, clinical, and regulatory aspects of their development. Topics covered range from the use of immunological correlates of efficacy, rather than efficacy per se, for the evaluation and licensure of vaccine combinations, to preserving a stable immunogenic... |
 | The Flaviviruses: Detection, Diagnosis and Vaccine Development, Volume 61 (Advances in Virus Research) Over 50% of known flaviviruses have been associated with human disease. The Flavivirus genus constitutes some of the most serious human pathogens including Japanese encephalitis, dengue and yellow fever. Flaviviruses are known for their complex life cycles and epidemic spread, and are considered a globally-emergent viral threat.Detection, Diagnosis and Vaccine Development, the third volume of The... |
| International Symposium on Immunization of Adult Birds With Inactivated Oil Adjuvant Vaccines (Developments in Biological Standardization, Volume 51) by Illustr Acting Editors - Y. Moreau & W. Hennessen | |
| FluMist flop may stymie vaccine development.(Infectious Diseases): An article from: Internal Medicine News by Timothy F. Kirn This digital document is an article from Internal Medicine News, published by International Medical News Group on June 1, 2004. The length of the article is 1011 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation... | |
 | Concepts in Vaccine Development |
| © 2008 BrightSurf.com |